Assessment of Hepatic Fibrosis Severity in Children Based on Direct Biomarkers and Calculated Indices: Minimally Invasive Approach
Pediatric pharmacology · 26.07.2026 · 23 (3) · 194-205
DOI: 10.15690/pf.v23i3.3064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric pharmacology, online erschienen am 26.07.2026. Verfasst von Sadig T. Fatullaev und 9 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Recently, the evidence base for modern methods of assessing liver fibrosis (LF) using serological biomarkers and calculated indices has been significantly expanded. The most promising markers include collagens of types I and III (COL1, COL3), hyaluronic acid (HA), growth differentiation factor-15 (GDF-15), monocyte chemotactic protein-1 (MCP-1), extracellular matrix protein-1 (ECM1), as well as APRI indices (Aspartate aminotransferase-to-platelet ratio index) and FIB-4 (Fibrosis-4 index). However, now the number of publications with the results of using this diagnostic complex in pediatric practice remains limited.
Objective
The aim of the study is to evaluate the diagnostic value of direct serological biomarkers (COL1, COL3, HA, GDF-15, MCP-1, ECM1) in combination with the APRI and FIB-4 indices for minimally invasive stratification of LF stages in children.
Methods
The study included 108 patients aged 2 years 4 months to 17 years 11 months (median age — 9.9 [6.9; 15.9] years) with chronic liver diseases of various etiologies, 51 of them with cryptogenic LF, 19 with glycogen storage diseases, 14 with autoimmune hepatitis, 14 with primary sclerosing cholangitis, 6 with Wilson disease, 2 with progressive familial intrahepatic cholestasis, 1 with glycogenic hepatopathy in the framework of Mauriac’s syndrome, 1 with Caroli disease. To determine the stage of LF, all children underwent two-dimensional shear-wave elasticity imaging (DSWE), evaluation of serum concentrations of direct LF biomarkers in vitro: GDF-15 (pg/mL); COL1 (ng/ml); COL3 (ng/ml); ECM1 (pg/mL) by Sandwich ELISA (enzyme-linked immunosorbent assay), and HA (ng/ml) by the method of general ELISA. Additionally, the APRI and FIB-4 indices were calculated.
Results
Concentrations of HA, GDF-15, and ECM1 in blood serum increased statistically significantly as LF progressed (p < 0.001 for all indicators). Data on statistically significant differences in COL1 (p < 0.001) and COL3 (p = 0.001) concentrations were obtained when distinguishing between early changes in hepatic parenchyma (stages F0–F1). When determining the threshold values of HA depending on the stage of LF, high sensitivity (> 90%) and specificity (> 94.6%) were found in differentiating pronounced structural changes in the liver from the early stages of fibrosis. When differentiating the F4 stage from F0, 100% sensitivity and 100% specificity were achieved at the GDF-15 level, 81.8% sensitivity and 90.6% specificity at the ECM1 level. The best indicators of sensitivity (70.3%) and specificity (69.4%) for COL3 were noted when distinguishing stages F0 from F1. The calculated FIB-4 and APRI indices demonstrated a significant increase in the median values in patients at late stages of LF: F4 from F0–F3 (p < 0.05) and F4 from F0–F2 (p < 0.011), respectively.
Conclusion
The serum concentrations of HA, GDF-15, ECM1, as well as the values of the calculated APRI and FIB-4 indices demonstrate unidirectional dynamics, increasing as the degree of LF in children increases. On the contrary, the concentrations of COL1 and COL3 decrease in this case at the stage of minimal fibrosis formation and remain low as the disease progresses compared with the F0 stage. The presented instrumental and laboratory complex can be considered as a promising minimally invasive diagnostic tool for stratification of LF stages in children.
Zitieren
APA
Fatullaev, S. T., Surkov, A. N., Gordeeva, O. B., Kotikova, K. I., Bessonov, E. E., Dzhgarkava, I., Izotova, N. A., Dobrotok, A. V., Guseynova, A. D., & Namazova-Baranova, L. S. (2026). Assessment of Hepatic Fibrosis Severity in Children Based on Direct Biomarkers and Calculated Indices: Minimally Invasive Approach. Pediatric pharmacology, 23(3), 194-205. https://doi.org/10.15690/pf.v23i3.3064
Vancouver
Fatullaev ST, Surkov AN, Gordeeva OB, Kotikova KI, Bessonov EE, Dzhgarkava I, et al. Assessment of Hepatic Fibrosis Severity in Children Based on Direct Biomarkers and Calculated Indices: Minimally Invasive Approach. Pediatric pharmacology. 2026;23(3):194-205. doi:10.15690/pf.v23i3.3064
BibTeX
@article{Fatullaev2026,
author = {Fatullaev, Sadig T. and Surkov, Andrej N. and Gordeeva, Olga B. and Kotikova, Kira I. and Bessonov, Evgenij E. and Dzhgarkava, Irine and Izotova, Natal’ya A. and Dobrotok, Albina V. and Guseynova, Albina D. and Namazova-Baranova, Leyla S.},
title = {Assessment of Hepatic Fibrosis Severity in Children Based on Direct Biomarkers and Calculated Indices: Minimally Invasive Approach},
journal = {Pediatric pharmacology},
year = {2026},
volume = {23},
number = {3},
pages = {194--205},
doi = {10.15690/pf.v23i3.3064}
}
EUVIMED